Xilio Therapeutics (XLO)
(Delayed Data from NSDQ)
$1.29 USD
-0.02 (-1.53%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $1.31 +0.02 (1.55%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XLO 1.29 -0.02(-1.53%)
Will XLO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for XLO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XLO
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
XLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for XLO
12 Health Care Stocks Moving In Wednesday's Intraday Session
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
TD Cowen Remains a Buy on Xilio Therapeutics (XLO)
XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results